Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$1.31 -0.8%	$1.45	$0.65 ▼ $2.12	$97.88M	2.29	343,761 shs	228,018 shs
CLSN Imunon		$2.22	$1.80 ▼ $15.75	$13.91M	2.27	150,471 shs	711 shs
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
GNPX Genprex	$2.13 -4.1%	$3.67	$2.09 ▼ $45.20	$4.07M	-0.61	74,206 shs	38,188 shs
SESN Sesen Bio		$10.50	$0.37 ▼ $12.58	$2.56B	0.83	1.07 million shs	93,330 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	+4.76%	+1.54%	-19.02%	+2.33%	+14.78%
CLSN Imunon	0.00%	0.00%	0.00%	0.00%	0.00%
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
GNPX Genprex	0.00%	-20.50%	-34.62%	-73.56%	-94.42%
SESN Sesen Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.7953 of 5 stars	3.5	5.0	0.0	0.0	2.0	1.7	0.6
CLSN Imunon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	4.2016 of 5 stars	3.5	5.0	0.0	4.7	0.6	0.8	1.3
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	3.00	Buy	$4.75	262.60% Upside
CLSN Imunon	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A
GNPX Genprex	3.00	Buy	$10.00	369.48% Upside
SESN Sesen Bio	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CLSN, CLSD, SESN, GNPX, and CTST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
4/3/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/25/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$10.00
3/14/2024	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/13/2024	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/13/2024	CLSD Clearside Biomedical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$8.23M	11.89	N/A	N/A	($0.25) per share	-5.24
CLSN Imunon	$500K	0.00	N/A	N/A	$9.66 per share	0.00
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
GNPX Genprex	N/A	N/A	N/A	N/A	$4.99 per share	N/A
SESN Sesen Bio	$40M	0.00	N/A	3.39	$0.78 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$32.49M	-$0.53	N/A	N/A	N/A	-394.91%	N/A	-85.31%	5/9/2024 (Estimated)
CLSN Imunon	-$20.77M	N/A	0.00	N/A	N/A	-5,229.80%	-50.18%	-36.94%	N/A
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	-$30.86M	-$24.80	N/A	N/A	N/A	N/A	-245.62%	-185.50%	5/27/2024 (Estimated)
SESN Sesen Bio	-$19.88M	-$0.10	N/A	N/A	N/A	N/A	6.70%	5.41%	N/A

Latest CLSN, CLSD, SESN, GNPX, and CTST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CLSD Clearside Biomedical	-$0.10	-$0.08	+$0.02	-$0.08	$3.40 million	$6.35 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	4.42	4.42
CLSN Imunon	0.13	6.52	6.52
CTST CannTrust	N/A	N/A	N/A
GNPX Genprex	N/A	2.31	2.31
SESN Sesen Bio	N/A	6.10	6.10

Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
CLSN Imunon	12.97%
CTST CannTrust	0.03%
GNPX Genprex	14.05%
SESN Sesen Bio	16.45%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	9.80%
CLSN Imunon	4.66%
CTST CannTrust	N/A
GNPX Genprex	11.54%
SESN Sesen Bio	3.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	74.72 million	67.40 million	Optionable
CLSN Imunon	27	7.10 million	6.77 million	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
GNPX Genprex	31	1.91 million	1.69 million	Optionable
SESN Sesen Bio	35	203.49 million	196.98 million	Optionable

CLSN, CLSD, SESN, GNPX, and CTST Headlines

Source	Headline
	Trey Mewes startribune.com - April 10 at 12:53 AM
	Devin Haney: biography, record, fights and more espn.com - December 9 at 5:50 PM
	Tyson Fury: Biography, record, fights and more espn.com - December 2 at 10:49 AM
	Why the Tucker Carlson Biography Sales Are So Pathetic thedailybeast.com - September 13 at 10:23 PM
	Sesen Bio (NASDAQ: SESN) fool.com - August 4 at 6:23 PM
	James McTeigue Biography & Movies tribute.ca - May 10 at 6:46 PM
	After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio bizjournals.com - March 6 at 7:17 PM
	Sesen Bio wins shareholder approval for Carisma merger msn.com - March 2 at 1:30 PM
	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics finance.yahoo.com - March 2 at 1:30 PM
	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results finance.yahoo.com - February 28 at 12:42 PM
	SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations benzinga.com - February 24 at 9:19 PM
	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma finance.yahoo.com - February 21 at 10:50 AM
	BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics stockhouse.com - February 17 at 8:59 PM
	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting businesswire.com - February 16 at 4:47 PM
	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger finance.yahoo.com - February 16 at 9:10 AM
	Sesen Bio reaches deal with investor group, paving way for Carisma merger endpts.com - February 15 at 2:11 PM
	Latest terms of Sesen Bio and Carisma merger appear to pass muster thepharmaletter.com - February 15 at 2:11 PM
	5 big dividend moves: Group 1 Automotive hikes by 20% \| Pro Recap finance.yahoo.com - February 15 at 9:11 AM
	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics finance.yahoo.com - February 15 at 9:11 AM
	Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group bizjournals.com - February 14 at 2:01 PM
	Sesen gains 11% on amended terms for merger with Carisma msn.com - February 14 at 9:00 AM
	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger finance.yahoo.com - February 14 at 9:00 AM
	Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago finance.yahoo.com - February 6 at 10:17 AM
	Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger finance.yahoo.com - February 2 at 7:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Clearside Biomedical

NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Imunon

NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Genprex

NASDAQ:GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Sesen Bio

NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial